SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to strong community support and ongoing building efforts, including IRL initiatives and new product teases like KENDU SPICE. Community members express conviction and encourage others to join the movement, emphasizing KENDU's potential to become a major brand. Discussions also highlight the upcoming KENDU Games release and various merchandise offerings.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as community members rally behind its grassroots foundation and fair distribution, highlighting its potential as a leading meme coin on the Bitcoin network. Discussion focuses on the growing $DOG treasury and the increasing recognition from major players in the crypto space. Some community members also express excitement about potential exchange listings and increased exposure to retail investors.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending due to recent earnings, where revenue increased, and full-year outlook was raised, despite a mixed market reaction. The community is debating whether the current price reflects the company's long-term potential in the AI space, with discussions around profitability targets and potential market manipulation. Bullish sentiment remains as some highlight strong fundamentals, recent analyst upgrades, and future growth catalysts, while others express concern over the stock's performance relative to its sector.

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium (CCD) is trending due to its recent partnership with bitcoin.com for age-verified stablecoin payments, sparking community excitement and discussions around its potential. Some view CCD as an undervalued privacy and identity-focused project with strong long-term potential, drawing comparisons to ZEC. The project's focus on compliant, enterprise-ready blockchain solutions and growing institutional interest are also key talking points.

Dogelon Mars

Dogelon Mars is trending amidst mixed community sentiment, with some expressing frustration over price movement and unrealized gains, while others remain hopeful and accumulate more tokens. The community is closely watching for potential catalysts like a significant burn or metaverse integration, but some express concern over broken promises from the development team. General market volatility and influence from broader crypto trends are also being discussed.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is trending amid discussions around potential ACA subsidy extensions and the impact of a possible government shutdown on healthcare. Community members are weighing the implications of Trump's comments on healthcare and potential impacts on insurance companies, while also considering Centene's financial outlook and potential for growth in the sector.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amid reports of a potential breakup into two separate companies, focusing on sauces and condiments versus grocery products, which has sparked discussion about unlocking shareholder value. While some are skeptical, pointing to existing debt and margin concerns, others see an opportunity for strategic focus and growth, especially with the high dividend yield becoming more attractive amidst potential rate cuts. Community members are actively debating whether this split will truly benefit the stock or if it's simply rearranging a struggling business.

Monero

Monero is trending as the community emphasizes its role as a leading privacy coin, with some anticipating a significant breakout despite past delistings from major exchanges. Discussions highlight Monero's potential use cases amidst growing concerns over financial surveillance and the rise of CBDCs. Community members are also actively discussing mining Monero, viewing it as a means to secure the network and accumulate value.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as the community rallies around the project's consistent daily activity and celebrates milestones like surpassing 500 watchers. References to 'Grind with Gladys' and sponsoring MMA fighter Karolina Arm are prominent, showcasing community engagement. The coin is also gaining attention for its commitment to onboarding more people to Web3.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending down sharply following news of a clinical hold on its MAGNITUDE trial due to liver toxicity concerns. The community is debating the severity of the issue, potential long-term impacts, and whether the sell-off is an overreaction, while also noting Cathie Wood's recent purchase of a million shares. Discussions include potential merger scenarios and speculation about insider information, alongside lowered price targets from analysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: LENZ Therapeutics (NASDAQ:LENZ) CFO Acquires 2,198 Shares of Stock

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) CFO Daniel Chevallard acquired 2,198 shares of LENZ Therapeutics stock in a transaction that occurred on Friday, November 7th. The stock was...

Brokers Set Expectations for LENZ Q3 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of LENZ Therapeutics in a note issued to...

William Blair Predicts Weaker Earnings for LENZ Therapeutics

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at William Blair decreased their FY2025 earnings per share estimates for LENZ Therapeutics in a report released on...

LENZ Therapeutics (NASDAQ:LENZ) Announces Earnings Results

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus...

LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Down - Time to Sell?

LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Down - Here's Why...

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +11.94% and +92.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

LENZ Therapeutics, Inc. (LENZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

LENZ Therapeutics, Inc. (LENZ) Upgraded to Buy: What Does It Mean for the Stock?

LENZ Therapeutics, Inc. (LENZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?

Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?

The consensus price target hints at a 30.9% upside potential for LENZ Therapeutics, Inc. (LENZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ Therapeutics Inc.

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$23.25
Prev Close	$22.96
Open	$22.31
Dividend Yield	0.00%
50-Day Moving Average	$38.39
Beta	1.06
Avg. Volume	1.17M
PE Ratio	-10.90

52-Week High	$50.40
52-Week Low	$16.54
Market Capitalization	$655.15M
EPS (Annual)	-$2.34
Price to Book	3.39
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

LENZ
LENZ Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LENZ News

LENZLENZ Therapeutics Inc.